Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
Public ClinicalTrials.gov record NCT04381832. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients With Metastatic Castrate Resistant Prostate Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of etrumadenant (AB928)-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).
Study identification
- NCT ID
- NCT04381832
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 173 participants
Conditions and interventions
Conditions
Interventions
- Etrumadenant Drug
- Zimberelimab Drug
- Quemliclustat Drug
- Enzalutamide Drug
- Docetaxel Drug
- SG Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 7, 2020 (Actual)
- Primary completion
- Aug 30, 2024 (Actual)
- Completion
- Aug 30, 2024 (Actual)
- Last update posted
- Jul 22, 2025
2020 – 2024
United States locations
- U.S. sites
- 17
- U.S. states
- 9
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The Oncology Institute of Hope & Innovation | Cerritos | California | 90703 | — |
| The University of California, Los Angeles | Encino | California | 91436 | — |
| The University of California, Irvine Medical Center | Orange | California | 92868 | — |
| Florida Cancer Specialists South | Sarasota | Florida | 34232 | — |
| Florida Cancer Specialists North | St. Petersburg | Florida | 33705 | — |
| Florida Cancer Specialists Panhandle | Tallahassee | Florida | 32308 | — |
| Florida Cancer Specialists East | West Palm Beach | Florida | 33401 | — |
| Northwestern University Feinberg School of Medicine | Chicago | Illinois | 60611 | — |
| Affinity Health Hope & Healing Cancer Services | Hinsdale | Illinois | 60521 | — |
| Johns Hopkins University | Baltimore | Maryland | 21287 | — |
| New York University, Langone Health | New York | New York | 01006 | — |
| Wilmot Cancer Institute Oncology, University of Rochester | Rochester | New York | 14642 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Tennessee Oncology - Chattanooga | Chattanooga | Tennessee | 37404 | — |
| Tennessee Oncology - Nashville | Nashville | Tennessee | 37203 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Medical Oncology Associates, PS (dba Summit Cancer Centers) | Spokane | Washington | 99208 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04381832, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 22, 2025 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04381832 live on ClinicalTrials.gov.